Clinical Development Lead Prostate (ACP3) at Bristol-Myers Squibb

San Diego, California, United States

Bristol-Myers Squibb Logo
Not SpecifiedCompensation
Senior (5 to 8 years), Expert & Leadership (9+ years)Experience Level
Full TimeJob Type
UnknownVisa
Biotechnology, Pharmaceuticals, OncologyIndustries

Requirements

  • MD or equivalent with sub-specialty training in oncology
  • At least 8 years of pharmaceutical/biotech experience in oncology solid tumor clinical development
  • Drug development experience in GU cancer, prostate cancer, lung cancer, or other solid tumor cancers
  • Radiopharmaceutical experience preferred but not required
  • Willing to travel approximately 30% of the time

Responsibilities

  • Interact with clinical investigators and thought leaders to design a clinical development plan for nominated drug candidates
  • Lead internal project teams, and partner with investigators and CROs to design and implement clinical studies
  • Contribute to writing of protocols, investigator brochures, clinical study reports, and review of other clinical trial and regulatory documents
  • Conduct investigator meetings and lead site qualification and initiation visits with clinical trial investigators
  • Execute and deploy drug development strategic plans, develop contingency plans, provide technical and strategic advice, and meet milestones and budgets
  • Translate findings from research and nonclinical studies into clinical development opportunities
  • Oversee Data Review and Independent Data Monitoring Committees
  • Conduct clinical trials using ethical guidelines relevant to the pharmaceutical industry, and ensure compliance with these external guidelines
  • Establish and maintain positive relationships with clinical trial investigators and thought leaders
  • Serve as clinical lead for regulatory interactions, including preparation of briefing documents and attendance and presentation at health authority meetings
  • Supervise and mentor clinical scientists and medical directors

Skills

Clinical Development
Prostate Cancer
IND Preparation
Regulatory Interactions
Phase 1 Trials
Phase 2 Trials
Phase 3 Trials
Medical Monitoring
Radiopharmaceuticals
Clinical Trial Design
Cross-Functional Collaboration

Bristol-Myers Squibb

Develops and delivers biopharmaceutical medicines

About Bristol-Myers Squibb

Bristol Myers Squibb (BMS) develops and delivers medicines aimed at treating serious diseases, focusing on areas like cancer, autoimmune diseases, and heart conditions. The company conducts extensive research and development to create new drugs, which are sold after receiving regulatory approval. BMS also produces generic drugs, offering affordable alternatives that meet the same quality standards as their branded counterparts. What sets BMS apart from competitors is its dual focus on both innovative and generic medicines, enhancing access to healthcare. The company's goal is to improve patient outcomes while maintaining a commitment to sustainability and corporate responsibility.

New York City, New YorkHeadquarters
1887Year Founded
$33,706.1MTotal Funding
IPOCompany Stage
Biotechnology, HealthcareIndustries
10,001+Employees

Benefits

Flexible Work Hours
Hybrid Work Options
Professional Development Budget

Risks

Increased competition in oncology from emerging biotech firms like ArsenalBio.
BMS's lawsuit over the 340B Drug Pricing Program may lead to regulatory challenges.
Rapid AI and digital tech evolution may pose integration challenges for BMS.

Differentiation

BMS focuses on innovative cancer treatments through collaborations like ArsenalBio for T cell therapies.
The company emphasizes digital health technologies, enhancing clinical trial management and patient engagement.
BMS offers both innovative and generic medicines, increasing affordable healthcare solutions.

Upsides

BMS's partnership with Medidata enhances clinical research processes and patient outcomes.
The collaboration with AI Proteins advances novel miniprotein-based therapeutics, expanding therapeutic modalities.
BMS's global license agreement with BioArctic expands its portfolio in neurodegenerative diseases.

Land your dream remote job 3x faster with AI